Regeneron Pharmaceuticals, Inc. / Telix Pharmaceuticals Limited
2026 · Co-Development · $2.1B · Complete
Announcement Sentiment
75
Strongly positive
Regeneron and Telix announced a 50/50 cost-and-profit-share collaboration to co-develop next-generation radiopharmaceutical therapies across four initial solid-tumor programs. Telix receives $40M upfront with per-program optionality to co-fund commercialization/profit-share or alternatively earn up to $2.1B in milestones plus low double-digit royalties. Also plans co-developed companion radio-diagnostics.